newsfilter
← Latest News
Business Wire·

Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

OBX
  • Obsidian Therapeutics presented updated efficacy & safety data for amsoki-cel in advanced melanoma at the 41st SITC Meeting, showing a 67% ORR (n=10/15), median PFS of 8.3 months, & median DOR not reached at 14.3 months follow-up.
  • Enrollment is ongoing in the registration-enabling cohort of the Phase 1/2 Agni-01 study, with completion expected by Q1 2027 & topline data anticipated by year-end 2027.
  • The Company strengthened its Board of Directors by appointing Mark Reisenauer in November 2026.
  • Cash, cash equivalents, & marketable securities totaled $324.4 million as of September 30, 2026, providing a runway into the second half of 2028.
  • Obsidian completed its transaction with Galera Therapeutics & began Nasdaq trading under ticker "OBX" on August 4, 2026, following a $350 million oversubscribed financing.
  • Research & development expenses were $27.5 million, general & administrative expenses were $10.3 million, & acquired in-process R&D expense was $15.1 million for the three months ended September 30, 2026.
  • The Company reported a net loss of $50.7 million ($1.23 per share) for the third quarter of 2026.
  • Amsoki-cel data showed no dose-limiting toxicities, treatment-related mortality, ICANS, or ICU transfers in the pooled safety set of 37 patients.
  • The Company published a Nature Medicine article summarizing safety & efficacy data from the FIH & Agni-01 trials as of May 5, 2026.
  • Phase 1 data for amsoki-cel in non-small cell lung cancer (NSCLC) within the Agni-01 trial is expected in the first half of 2027.